ArticleMolecular pharmaceutics2015
Synthesis and Evaluation of 64Cu-DOTA-NT-Cy5.5 as a Dual-Modality PET/Fluorescence Probe to Image Neurotensin Receptor-Positive Tumor.
Article in Molecular pharmaceutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03516045 (A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Dual-modality theranostics probes: sintegrative strategies for precision management of oncologic malignancies.Life medicine · 2026Review
- Advances in neurotensin receptor 1-targeted molecular probes for tumor molecular imaging and therapy.Frontiers in oncology · 2026Review
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Dual-Labeled Small Peptides in Cancer Imaging and Fluorescence-Guided Surgery: Progress and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Dually Labeled Neurotensin NTSJournal of medicinal chemistry · 2024Article
- Chelator boosted tumor-retention and pharmacokinetic properties: development ofEuropean journal of nuclear medicine and molecular imaging · 2024Article
- Translocator Protein 18 kDa (TSPO): A Promising Molecular Target for Image-Guided Surgery of Solid Cancers.Advanced pharmaceutical bulletin · 2024Review
- Article
- Dual-Labelling Strategies for Nuclear and Fluorescence Molecular Imaging: Current Status and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Fluorescence Image-Guided Surgery - a Perspective on Contrast Agent Development.Proceedings of SPIE--the International Society for Optical Engineering · 2020Article
- Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use.European journal of nuclear medicine and molecular imaging · 2019Article
- pH-dependent and cathepsin B activable CaCOInternational journal of nanomedicine · 2019Article
- Review
- Molecular Imaging of P-glycoprotein in Chemoresistant Tumors Using a Dual-Modality PET/Fluorescence Probe.Molecular pharmaceutics · 2017Article
- Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma.Amino acids · 2017Article
- Conformationally Strained trans-Cyclooctene (sTCO) Enables the Rapid Construction of (18)F-PET Probes via Tetrazine Ligation.Theranostics · 2016Article
- Radiolabeled theranostics: magnetic and gold nanoparticles.BioImpacts : BI · 2016Review
- Imaging Neurotensin Receptor in Prostate Cancer WithMolecular imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Overexpression of neurotensin receptors (NTRs) has been suggested to play important roles in the growth and survival of a variety of tumor types. The aim of this study is to develop a dual-modality probe (64Cu -DOTA-NT-Cy5.5) for imaging NTR1 expression in vivo with both positron emission tomography (PET) and fluorescence. In this approach, the thiol group and N terminal amino group of neurotensin analogue (Cys-NT) were chemically modified with Cy5.5 dye and DOTA chelator, respectively. After radiolabeling with 64Cu, the resulting probe (64Cu-DOTA-NT-Cy5.5) was evaluated in NTR1 positive HT-29 tumor model. Small animal PET quantification analysis demonstrated that the tumor uptake was 1.91±0.22 and 1.79±0.16%ID/g at 1 and 4 h postinjection (p.i.), respectively. The tumor-to-muscle ratio was 17.44±3.25 at 4 h p.i. based on biodistribution. Receptor specificity was confirmed by the successful blocking experiment at 4 h p.i. (0.42±0.05%ID/g). In parallel with PET experiment, fluorescence imaging was also performed, which demonstrated prominent tumor uptake in HT-29 model. As a proof of concept, an imaging guided surgery was performed to the fluorescent moiety of this probe and could provide potential surgery guidance for NTR positive patients. In summary, our results clearly indicated that the dual-modality probe, 64Cu-DOTA-NT-Cy5.5, could serve as a promising agent to image NTR positive tumors in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.